How PFE (Pfizer) Makes Money in 2026: A Deep-Dive With Income Statement

Welcome to the Value Sense Blog, your resource for insights on the stock market! At Value Sense, we focus on intrinsic value tools and offer stock ideas with undervalued companies. Dive into our research products and learn more about our unique approach at valuesense.io

Explore diverse stock ideas covering technology, healthcare, and commodities sectors. Our insights are crafted to help investors spot opportunities in undervalued growth stocks, enhancing potential returns. Visit us to see evaluations and in-depth market research.

Understanding how a pharmaceutical giant like Pfizer makes money is essential for investors and anyone interested in the business of healthcare. In this post, we break down Pfizer's quarterly income statement (Q4 2025) using a Sankey chart to visualize the financial flows — what comes in, where it goes, and what's left as profit.

Quick Pfizer Overview

Pfizer operates as a leading biopharmaceutical company, developing, manufacturing, and marketing innovative medicines and vaccines worldwide. Revenue comes primarily from sales of pharmaceutical products across therapeutic areas like oncology, immunology, and rare diseases. The company also has smaller contributions from contract manufacturing and other product revenues.

Revenue Breakdown

• Total Revenue (Q4 2025): $17.6B (-1.2% YoY)
  • Global Pharmaceuticals: $17.1B (97.6% of total)
  • Business Innovation (Pfizer CentreOne): $0.409B (2.3% of total)
  • Other Revenue by Product: $4.0B (0.0% of total)
  • Growth is powered by expansion in the Pfizer CentreOne segment, despite a slight overall decline led by challenges in legacy products.

Gross Profit and Margins

• Gross Profit: $12.3B (70.0% gross margin)
  • Cost of Revenue: $5.3B (-10.8% YoY)
  • Pfizer maintains robust margins due to its scalable intellectual property portfolio, favorable pricing power in patented drugs, and efficiencies in manufacturing.
• Most costs come from manufacturing raw materials, production overhead, and royalties for pharmaceutical ingredients.

Operating Income and Expenses

• Operating Income: $3.7B (+15.7% YoY, 21.0% margin)
• Operating Expenses: $8.6B (-0.8% YoY)
  • R&D: $3.4B (+12.6% YoY, 19.5% of revenue) — focused on pipeline development in oncology, gene therapies, and vaccines
  • SG&A: $3.7B (+12.6% YoY, 21.3% of revenue) — driven by sales force expansion and administrative costs for global operations
  • Pfizer continues to prioritize innovation while maintaining efficiency through cost controls in non-core areas.

Net Income

• Pre-Tax Income: $1.6B (+16,320.0% YoY, 9.4% margin)
• Income Tax: $2.0B (0.1% effective tax rate)
• Net Income: $1.6B (+0.0% YoY, 9.4% net margin)
• Pfizer converts a significant portion of sales into profit due to scalability of its drug portfolio, high gross margins, and strategic tax structuring.

Most investors waste time on the wrong metrics. We've spent 10,000+ hours perfecting our value investing engine to find what actually matters.

Want to see what we'll uncover next - before everyone else does?

Find Hidden Gems First!

What Drives Pfizer's Money Machine?

• Global Pharmaceuticals: 97.6%+ of revenue / Core driver from blockbuster drugs in immunology, oncology, and cardiovascular therapies
• Pipeline Productivity: R&D investments support over 100 programs, with key approvals boosting future revenues
• Pfizer CentreOne Investments: Contract manufacturing for third parties, growing at 25.8% YoY
• Future growth areas: Rare disease therapies and obesity treatments, though not yet profitable at scale

Visualizing Pfizer's Financial Flows

The Sankey chart below visualizes how each dollar flows from gross revenue, through costs and expenses, down to net income. This helps investors spot where value is created, what areas weigh on profits, and how efficiently the company operates.

• Most revenue flows into gross profit, with operating expenses (especially SG&A and R&D) taking the largest chunk.
• Even after large investments in R&D, 9.4% of revenue drops to the bottom line.

Key Takeaways

• Pfizer's money comes overwhelmingly from Global Pharmaceuticals
• High gross and net margins illustrate the power of Pfizer's patent-protected drug portfolio
• Heavy investment in R&D, balanced by efficiency in operating costs
• Ongoing growth is driven by pipeline advancements and contract manufacturing

Explore More Investment Opportunities

For investors seeking undervalued companies with high fundamental quality, our analytics team provides curated stock lists:

📌 50 Undervalued Stocks (Best overall value plays for 2026)

📌 50 Undervalued Dividend Stocks (For income-focused investors)

📌 50 Undervalued Growth Stocks (High-growth potential with strong fundamentals)

🔍 Check out these stocks on the Value Sense platform for free!

FAQ About Pfizer's Income Statement

1. What is the main source of Pfizer's revenue in 2025?

Pfizer generates over 97.6% of its revenue from Global Pharmaceuticals. Additional revenue sources include Business Innovation (Pfizer CentreOne) at 2.3%.

2. How profitable is Pfizer in Q4 2025?

Pfizer reported net income of $1.6B in Q4 2025, with a net margin of approximately 9.4%, reflecting strong profitability driven by high gross margins and operating leverage.

3. What are the largest expense categories for Pfizer?

The biggest expenses on Pfizer's income statement are operating expenses, particularly Research & Development (R&D) and Sales, General & Administrative (SG&A) costs. R&D investment reached $3.4B in Q4 2025, as Pfizer prioritizes oncology and vaccine development.

4. Why does Other Revenue by Product operate at a loss?

Other Revenue by Product, despite generating $4.0B in revenue, posted challenges with an -84.0% YoY decline in Q4 2025. This is because Pfizer aggressively invests in transitioning from legacy products, believing these will drive long-term growth—even if the category is unprofitable today.

5. How does Pfizer's effective tax rate compare to previous years?

Pfizer's effective tax rate in Q4 2025 was 0.1%, lower than previous years. This low rate is primarily due to tax benefits from international structuring and other credits.